Mack, P. C., Gandara, D. R., Omori, A., Grimminger, P. P., Lenz, H.-J., Joshi, M.-B., … Danenberg, K. D. (2009). KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies. In JOURNAL OF THORACIC ONCOLOGY (Vol. 4, pp. S350–S350). LIPPINCOTT WILLIAMS & WILKINS.

Mack, Philip C., David R. Gandara, Akiko Omori, Peter P. Grimminger, Heinz-Josef Lenz, Mary-Beth M. Joshi, David H. Harpole, and Kathleeen D. Danenberg. “KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies.” In JOURNAL OF THORACIC ONCOLOGY, 4:S350–S350. LIPPINCOTT WILLIAMS & WILKINS, 2009.

Mack PC, Gandara DR, Omori A, Grimminger PP, Lenz H-J, Joshi M-BM, et al. KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies. In: JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S350–S350.

Mack, Philip C., et al. “KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies.” JOURNAL OF THORACIC ONCOLOGY, vol. 4, no. 9, LIPPINCOTT WILLIAMS & WILKINS, 2009, pp. S350–S350.

Mack PC, Gandara DR, Omori A, Grimminger PP, Lenz H-J, Joshi M-BM, Harpole DH, Danenberg KD. KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S350–S350.